👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Bard convinces U.S. appeals court to revive medical-injection device patents

Published 02/17/2023, 04:28 PM
Updated 02/17/2023, 04:35 PM
BDX
-
ANGO
-

By Blake Brittain

(Reuters) - Becton Dickinson (NYSE:BDX)'s C.R. Bard Inc on Friday won a ruling from a U.S. appeals court reinstating three patents related to its PowerPort devices for delivering repeated medical injections.

The decision from the Washington, D.C.-based U.S. Court of Appeals for the Federal Circuit revives a long-running infringement lawsuit Bard brought against Pennsylvania-based Medical Components Inc, which makes competing devices.

The court on Friday also gave Medcomp a new chance to prove that a patent it had accused Bard of infringing was valid.

Medcomp had no comment on the ruling. Representatives for Becton Dickinson did not immediately respond to a request for comment.

Bard sued Medcomp in 2012 over MedComp's Pro-Fuse CT and Dignity devices in Utah federal court. Bard accused the devices of infringing patents related to its PowerPort, an "access port" for delivering repeated injections of fluids like medicine or blood to patients without using invasive surgeries or new intravenous lines. Medcomp countersued Bard for infringing one of its patents.

Becton Dickinson's medication delivery devices, including the PowerPort, earned the company more than $2.4 billion in sales last fiscal year, according to a company report with the U.S. Securities and Exchange Commission.

The case was paused for seven years based on related proceedings at the U.S. Patent and Trademark Office.

The Utah court found both companies' patents invalid in 2021. It said the patents, which cover markings used to differentiate between types of ports that are visible on X-rays, covered unpatentable abstract ideas.

The Federal Circuit revived the patents on Friday, citing its 2020 decision in a related dispute between Bard and rival AngioDynamics (NASDAQ:ANGO) Inc.

Bard's patents, like the ones in the AngioDynamics case, covered a novel way to use radiographic markers to convey information, the appeals court said.

The Federal Circuit also ordered the Utah court to reconsider whether Medcomp's similar patent was valid.

The case is C.R. Bard Inc v. Medical Components Inc, U.S. Court of Appeals for the Federal Circuit, No. 22-1136.

© Reuters. The United States Court of Appeals for the Federal Circuit is seen in Washington, D.C., U.S., August 30, 2020. REUTERS/Andrew Kelly

For Bard: Kathleen Sullivan of Quinn Emanuel Urquhart & Sullivan

For Medcomp: Alfred Zaher of Montgomery McCracken Walker & Rhoads

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.